PI Trade Names and Active Ingredients containing Arixtra. 1 Documents available. Need more information on a product? Search the Australian Register of. Mylan manufactures ARIXTRA®* (fondaparinux sodium) Injection, Solution ( Arixtra) in strengths of 25 mg05 mL 5 mgmL5 mg04 mL mgmL75 mg06 mL injection of Arixtra mg in young healthy subjects are provided in Table 1 below: . Arixtra mg once daily following hip fracture surgery, patients were.
|Published (Last):||5 January 2016|
|PDF File Size:||16.61 Mb|
|ePub File Size:||11.81 Mb|
|Price:||Free* [*Free Regsitration Required]|
Clinical practice guidelines recommend low molecular weight heparin for the prevention and treatment of venous thromboembolism during pregnancy. Fondaparinux does not inactivate thrombin factor IIa and has no known effect on platelet function.
If concurrent therapy is warranted, significant initial dosage reductions e. Since ginkgo produces clinically-significant antiplatelet wrixtra, it should be used cautiously in patients drugs that inhibit platelet aggregation or pose a risk for bleeding, such as anticoagulants.
Long-term concomitant treatment with edoxaban and other anticoagulants is not recommended; short-term use may be necessary for patients aarixtra to or from edoxaban. Major Prasterone DHEA is contraindicated for use in patients with active deep vein thrombosis, pulmonary embolism or history of these conditions. This may be a particular safety concern for the use of fondaparinux in children.
Moderate An additive risk of bleeding may be seen in thrombocytopenic patients receiving antineoplastic agents and anticoagulants concomitantly. If unexpected changes in coagulation parameters occur, fondaparinux should be discontinued. Avoid concurrent use of herbs which interact with warfarin when possible.
Patients receiving warfarin that initiate concomitant icosapent ethyl therapy should have their INR monitored more closely and the dose of warfarin adjusted accordingly. In-vitro cross-reactivity with antibodies that produce heparin-induced thrombocytopenia has not been observed.
Patients receiving warfarin that initiate concomitant cod liver oil therapy should have their INR monitored more closely and the dose of warfarin adjusted accordingly.
Patients, especially those with dental disease, should be instructed in proper oral hygiene, including caution in use of regular toothbrushes, dental floss, and toothpicks. Ginkgo, Ginkgo biloba is reported to inhibit platelet aggregation and several case reports describe bleeding complications with Ginkgo biloba, with or without concomitant drug therapy. The usual duration of administration of fondaparinux is 5—9 days; up to 26 days has been studied. Per the manufacturer of ticlopidine, if a patient is switched from an anticoagulant or a thrombolytic agent to pu, the former drug should be discontinued prior to the administration of ticlopidine.
All products differ in their manufacturing process, activity, and dosage. The mean duration of fondaparinux in the study was 6 days. At recommended doses, fibrinolytic ip or bleeding time is not altered. Moderate The concomitant use of ibrutinib and anticoagulant agents such as fondaparinux may increase the risk of bleeding; monitor patients for signs of bleeding.
Risk factors include those undergoing surgery with general anesthesia lasting more than 45 minutes who are 1 more than 60 years or 2 more than 40 years with at least 1 of the following: Concomitant treatment with warfarin should be initiated as soon as possible, usually within 72 hours. While some patients who experienced bleeding during ado-trastuzumab therapy were also receiving anticoagulation therapy, others had no known additional risk factors.
Ginger inhibits thromboxane synthetase platelet aggregation inducer and is a prostacyclin agonist. Minor Agents, such as anticoagulants, that decrease clotting arixrta decrease the efficacy of photosensitizing agents used in photodynamic therapy. Moderate Increased bruising or bleeding at the injection site may occur when using hyaluronate sodium with anticoagulants, including fondaparinux, especially if used within the 3 weeks prior to the procedure.
Minor The intramuscular rabies immune globulin, human RIG should arixtga administered arixtta to persons receiving anticoagulants. Major An additive risk of bleeding may be seen in thrombocytopenic patients receiving antineoplastic agents and anticoagulants concomitantly.
Use nintedanib in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk. Moderate An additive risk of bleeding may be aarixtra in thrombocytopenic patients receiving antineoplastic agents in combination with anticoagulants.
The usual duration of administration is 5 to 9 days; up to 10 days has been administered. There are no data on the presence of fondaparinux in human milk or the effects on milk production.
Moderate Give the extended-release injectable suspension of arixtrra cautiously to patients taking anticoagulants. Major Discontinue thrombin inhibitors before starting fondaparinux due to the increased bleeding risk, unless these agents are essential. Moderate There have been no documented pharmacokinetic interactions of fondaparinux with other drugs.
The INR should be closely monitored during concurrent therapy with warfarin, particularly during the initiation or termination phases of sulfinpyrazone treatment. During one of the available, published clinical trials in patients with osteoarthritis, those patients with bleeding disorders or using anticoagulants or antiplatelets were excluded from enrollment. Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide: Moderate Because dipyridamole is a platelet inhibitor, there is a potential additive risk for arixrra if dipyridamole is given in combination with other agents that affect hemostasis.
TGA eBS – Product and Consumer Medicine Information
Moderate Patients should be instructed to monitor for signs and symptoms of bleeding while taking vilazodone concurrently with anticoagulants and to promptly report any bleeding events to the practitioner. Although these effects have not been confirmed in published medical literature or during clinical studies, clinicians should consider using methylsulfonylmethane, MSM with caution in patients who are taking anticoagulants such as warfarin until data confirming the safety of MSM in patients taking these drugs are available.
The pharmacodynamic activity and risk of hemorrhage with antithrombotic agents are increased if coadministered with defibrotide. Theoretically, fondaparinux should not cause HIT because it does not bind to platelet factor 4. In regard to warfarin, published data are limited to a random case report; however, the product labeling for warfarin ppi garlic as having potential for interaction due to additive pharmacologic activity. Consider additional monitoring when concomitant use is medically necessary.